Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Jiaxing Antikang Biotechnology

Request full access

A drug developer focused on respiratory anti-infections

Kaohsiung, TaiwanFounded 2018Biotech & Life Sciences

About Jiaxing Antikang Biotechnology

Jiaxing Antikang Biotechnology, established on June 26, 2018, is a clinical-stage pharmaceutical company concentrating on the development of small molecule therapeutics for respiratory infections and pain management. The firm is guided by a seasoned leadership team with deep roots in pharmaceutical sciences. Chairman Jiang Weiping holds a Ph.D. in Pharmacy from China Pharmaceutical University and brings 39 years of comprehensive experience in drug research and development, production, and management. He is joined by co-founder and CEO, Zhu Xiaoyun, who holds a doctorate in medicinal chemistry. Their collective expertise forms the foundation of the company's scientific direction and strategic operations.

The company's business model is centered on the in-house research, development, and eventual commercialization of a pipeline of drug candidates that address unmet clinical needs. By leveraging a technology platform focused on metabolically differentiated small molecules, Antikang has established a technical barrier in areas like innovative drug design, DMPK (Drug Metabolism and Pharmacokinetics) technology research, and the development of formulations for special patient populations, such as children. The company's revenue generation will be contingent on the successful clinical development and market approval of its products, likely through direct sales and potential licensing or partnership agreements. The company's scientific and research team is further strengthened by the leadership of several academicians.

Antikang Biotechnology's product pipeline features several promising candidates. Its lead asset is ADC189 (Madeuteranovir), a novel anti-influenza drug designed for a "one-time cure." This drug has shown significant clinical progress in trials for both adults and children, with formulations in tablets and granules. Beyond influenza, the pipeline includes ADC789, a suspension for treating Respiratory Syncytial Virus (RSV); ADC101, a new-generation super-antibiotic for mycoplasma infections; and ADC308, a tablet aimed at treating endometriosis and uterine fibroids, a condition with limited treatment options in the domestic market. The company has successfully raised significant capital to advance these programs, completing an A-round financing of over 200 million yuan in June 2024, followed by an A+ round in September 2025, with participation from notable investors including Simcere Pharmaceutical, Huajin Investment, and existing shareholder Co-stone Capital.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
19.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2024 $28M $138M Wenzhou Capital · Jiarui future star · Songze Capital · Shunjie Health ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Proxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation New York City, United States Operational 77 $80M $320M
Kolate AIAdvanced analytics platform accelerating drug development with real-time insights and competitor monitoring Montgomery Township, United States Operational
SanegeneBioDeveloping targeted RNAi-based medicines for obesity, cardiometabolic and autoimmune diseases Woburn, United States Operational
Pattern BiosciencesBuilds biomolecular computers that run molecular programs in cells to treat cancer and other diseases South San Francisco, United States Operational
BioOrbitBioOrbit is space manufacturing company developing hardware for the large-scale crystallisation of protein drugs London, United Kingdom Operational
Superluminal MedicinesGenerative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created Boston, United States Operational
PhaseVUses advanced algorithms to optimize clinical trials, improving success rates, efficiency, and uncovering hidden signals in the data Tel Aviv-Yafo, Israel Operational
New BiologixEngineered cell line technology that produces safe and effective AAV drugs for gene therapy, making treatments more affordable and accessible Epalinges, Switzerland Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Jiaxing Antikang Biotechnology in the Kaohsiung ecosystem

Live from Dealroom

The Jiaxing Antikang Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

  • Simcere Pharma
  • Huajin Investment
  • Wenzhou Capital
  • Jiarui future star
  • Songze Capital
  • Shunjie Health
  • Huajin Avenue
  • Jiaxing New Venture Capital
  • Cowin Capital
  • GSR United Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇹🇼 Taiwan · Kaohsiung HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Jiaxing Antikang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Jiaxing Antikang Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.